Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

LEVAMISOLE PHOSPHATE

NFPA

PRODUCT USE

Anthelmintic for sheep and cattle.

SYNONYMS

C11-H12-N2-S.H3PO4, "imidazo[2.1-b]thiazole, 2, 3, 5, 6-tetrahydro-6-phenyl-, (S)-,
phosphate(1:1)", "imidazo[2.1-b]thiazole, 2, 3, 5, 6-tetrahydro-6-phenyl-, (S)-,
phosphate(1:1)", "imidazo(2, 1-b)thiazole, 2, 3, 5, 6-tetrahydro-6-phenyl-, phosphate
(1:1), (-)-", "imidazo(2, 1-b)thiazole, 2, 3, 5, 6-tetrahydro-6-phenyl-, phosphate (1:
1), (-)-", "(-)-2, 3, 5, 6-tetrahydro-6-phenylimidazo(2, 1-b)thiazole phosphate", "(-)-2,
3, 5, 6-tetrahydro-6-phenylimidazo(2, 1-b)thiazole phosphate", anthelmintic

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

May cause long- term adverse effects in the aquatic environment.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Although ingestion is not thought to produce harmful effects, the material may still be damaging to the health of the individual following ingestion, especially where pre-  existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality (death) rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.  Immunostimulants, especially when given for prolonged periods produce a range of adverse and diverse effects. In common with other immunomodulators, therapeutic use of this class of drug may exacerbate the primary underlaying disease. Hypersensitivity reactions such as fever, an influenza-like syndrome, arthralgia, muscle pain, skin rashes and cutaneous vasculitis, may occur. Central nervous system effects such as fatigue, headache, confusion, insomnia, dizziness, excitation and convulsions have been reported. Other side-  effects include haematological abnormalities such as agranulocytosis, leukopenia and thrombocytopenia and gastrointestinal disturbances, such as abnormal taste in the mouth.  As absorption of phosphates from the bowel is poor, poisoning this way is less likely. Effects can include vomiting, tiredness, fever, diarrhea, low blood pressure, slow pulse, cyanosis, spasms of the wrist, coma and severe body spasms.  

EYE

  Although the material is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn).  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Sensitization may result in allergic dermatitis responses includingrash, itching, hives or swelling of extremities.  

INHALED

  The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.  Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.  

CHRONIC HEALTH EFFECTS

  Principal routes of exposure are by accidental skin and eye contact andinhalation of generated dusts.  Sodium phosphate dibasic can cause stones in the kidney, loss of mineral from the bones and loss of thyroid gland function.